A/Prof Jim Whittle
Honorary (Senior Fellow)
Department of Medical Biology (WEHI)
88 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
An integrative spatial multi-omic workflow for unified analysis of tumor tissue
DOI: 10.1016/j.crmeth.2026.1013062026
Journal article
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps1-10-072026
Journal article
Patient-derived organoids and neurospheres recapitulate salient features of primary tumor heterogeneity
DOI: 10.1093/noajnl/vdaf2472025
Journal article
TIRE-seq simplifies transcriptomics via integrated RNA capture and library preparation
DOI: 10.1038/s41598-025-98282-82025
Journal article
TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study
DOI: 10.1093/neuonc/noaf201.16762025
Journal article
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
DOI: 10.1038/s41591-025-03884-42019
Journal article
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
DOI: 10.1158/2159-8290.CD-18-1151
RECENT SCHOLARLY WORKS
2025
Journal article
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
DOI: 10.1016/S0140-6736(25)00986-92025
Journal article
Abstract P2-07-18: Results from PALVEN: A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL2-Positive Metastatic Breast Cancer
DOI: 10.1158/1557-3265.sabcs24-p2-07-182025
Journal article
Residual Disease as a Decider
DOI: 10.1016/j.ijrobp.2024.12.0512025
Journal article
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
DOI: 10.1200/jco.2025.43.16_suppl.3014